Reference drugs for triple combination test drug in Russia [Design Issues]

posted by Yura – Belarus, 2019-11-19 21:51 (916 d 00:40 ago) – Posting: # 20830
Views: 4,131

(edited by mittyri on 2019-11-19 22:50)

Hi Beholder,
There is no reason for the regulator not to want to check section 4.5 of the Guideline on clinical development of fixed combination medicinal products :|>
Kind regards,
Yura


Edit: Guideline linked. Also changed the name in signature to the usual one[Mittyri]

Complete thread:

UA Flag
Activity
 Admin contact
22,092 posts in 4,630 threads, 1,567 registered users;
online 12 (0 registered, 12 guests [including 8 identified bots]).
Forum time: Monday 23:32 CEST (Europe/Vienna)

There is no adequate defense, except stupidity,
against the impact of a new idea.    Percy Williams Bridgman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5